ZYMEWORKS INC. - COMMON STOCK

14,14

24-декабря-24 13:45:00

15 мин. задержка

Акции

-0,14

-0,98%

Сегодняшний диапазон

13,85 - 14,35

ISIN

N/A

Источник

NASDAQ

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

12 дек 2024 08:30:00 Источник Nasdaq GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences

21 ноя 2024 06:05:00 Источник Nasdaq GlobeNewswire
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

21 ноя 2024 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

05 ноя 2024 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results

31 окт 2024 16:05:00 Источник Nasdaq GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences

29 окт 2024 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

25 окт 2024 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

21 окт 2024 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

10 окт 2024 06:30:00 Источник Nasdaq GlobeNewswire
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

18 сен 2024 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

03 сен 2024 16:30:00 Источник Nasdaq GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences

22 авг 2024 06:30:00 Источник Nasdaq GlobeNewswire
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock

01 авг 2024 16:10:51 Источник Nasdaq GlobeNewswire
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results

01 авг 2024 16:05:01 Источник Nasdaq GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences

30 июл 2024 06:30:00 Источник Nasdaq GlobeNewswire
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

25 июл 2024 16:30:00 Источник Nasdaq GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate

22 июл 2024 06:00:38 Источник Nasdaq GlobeNewswire
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

11 июл 2024 06:30:00 Источник Nasdaq GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

17 июн 2024 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

10 июн 2024 06:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.